Questcor Pharmaceuticals (QCOR) Scheduled to Post Quarterly Earnings on Tuesday
Questcor Pharmaceuticals (NASDAQ:QCOR) is scheduled to release its Q313 earnings data on Tuesday, October 29th. Analysts expect Questcor Pharmaceuticals to post earnings of $1.29 per share and revenue of $199.70 million for the quarter.
Questcor Pharmaceuticals (NASDAQ:QCOR) last released its earnings data on Tuesday, July 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.16. The company had revenue of $184.60 million for the quarter, compared to the consensus estimate of $168.96 million. During the same quarter in the previous year, the company posted $0.65 earnings per share. The company’s revenue for the quarter was up 64.1% on a year-over-year basis. On average, analysts expect Questcor Pharmaceuticals to post $4.83 EPS for the current fiscal year and $5.81 EPS for the next fiscal year.
Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) opened at 68.40 on Monday. Questcor Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $72.43. The stock’s 50-day moving average is $65.66 and its 200-day moving average is $44.03. The company has a market cap of $4.031 billion and a P/E ratio of 18.36.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, October 30th. Investors of record on Tuesday, October 22nd will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.75%. The ex-dividend date of this dividend is Friday, October 18th. This is an increase from Questcor Pharmaceuticals’s previous quarterly dividend of $0.25.
Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, October 1st. They now have a $66.40 price target on the stock. On the ratings front, analysts at Ned Davis Research downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Monday, September 30th. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Questcor Pharmaceuticals in a research note to investors on Tuesday, September 17th. They set a “neutral” rating and a $71.00 price target on the stock. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $73.37.
In other Questcor Pharmaceuticals news, Director Virgil Thompson sold 2,500 shares of the stock on the open market in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $60.50, for a total value of $151,250.00. Following the completion of the transaction, the director now directly owns 29,867 shares in the company, valued at approximately $1,806,954. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.